ArticlePloS one2025
Epidemiological trends in alcoholic cardiomyopathy burden: A 32-year global and Chinese analysis (1990-2021) with projections to 2036.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcoholic cardiomyopathy (ACM), a preventable yet overlooked cardiomyopathy subtype, disproportionately affects chronic alcohol users through alcohol-induced myocardial damage. Characterized by delayed clinical onset, ACM typically manifests as irreversible heart failure in middle age (45-69 years), creating missed opportunities for early intervention. Despite global cardiovascular mortality declines, ACM burden continues rising paradoxically in certain middle-high income countries like China, revealing gaps in current prevention strategies. This study systematically evaluates ACM's global burden through prevalence, mortality and disability-adjusted life years (DALYs) metrics, using WHO-standardized methods to characterize spatiotemporal patterns across global, national, and subnational strata.
methodsWe utilized the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 methodological framework to estimate the age-standardized rates (ASRs) of prevalenceand, mortality and DALYs for ACM. These estimates were stratified across key demographic dimensions including: Age groups (15-95+ years), Sex, Geographical regions (21 GBD-defined regions), the Socio-Demographic Index (SDI) quintiles, 204 countries and territories during the observation period 1990-2021. Furthermore, we employed Bayesian Age-Period-Cohort (BAPC) modeling with integrated nested Laplace approximations to project disease burden trajectories through 2036, incorporating uncertainty quantification via Markov chain Monte Carlo simulations.
resultsGlobally, ACM burden showed significant declines from 1990 to 2021, with age-standardized rates decreasing by 22.5-37.1% across prevalence, mortality and disability measures. However, China experienced a 200.4% case increase during this period, with rising mortality and disability rates contrary to global trends. The disease disproportionately affected males and middle-aged adults (45-69 years), with pronounced regional disparities in middle-high SDI areas. While population growth primarily drove disability-adjusted life year (DALY) increases, these regions also showed greatest potential for burden reduction through targeted interventions. Projections suggest continued global declines but only modest improvements in China through 2036.
conclusionIn 2021, ACM remained a significant global health burden, particularly affecting middle-aged and elderly populations with distinct demographic disparities. This study identified three critical issues: China's unique epidemiological patterns, optimal intervention timing for high-risk populations, and sex-specific pathogenic mechanisms. Future research should prioritize developing precision prevention strategies for high-burden regions, including population-based alcohol control policies, early screening programs (especially for males aged 45-69), and personalized secondary prevention measures. Middle-high SDI regions warrant particular attention as priority intervention areas requiring cost-effectiveness implementation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.